“Stress and strain that the acute illness can put on your body can activate or worsen some other underlying disease processes. Probably the most significant is heart disease, heart failure or major ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

However, he emphasizes that the flu, COVID-19, and RSV vaccines are all safe, effective, and well-researched. Another infectious disease that physicians are keeping their eyes on is a strain of avian ...

RSV prevention among children, including nirsevimab and the maternal RSVpreF vaccine, may be associated with a reduction in pediatric ICU utilization.

COVID-19, influenza, and RSV vaccination coverage is low among nursing home residents early in the 2024 to 2025 season.

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.DyCR3BqR.js ...

GSK and Zhifei revise and extend strategic vaccine collaboration in China: London, UK Friday, December 6, 2024, 10:00 Hrs [IST] GSK plc announced that it has entered into an agree ...

alongside a new collaboration on the RSV vaccine, Arexvy. Despite a financial revisit to the deal, which now stands at £2.3 ...

This briefing covers significant developments in health, including a revised deal between GSK and China's Zhifei, FDA ...

GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034.